LOGO
LOGO

Quick Facts

Singtel FY25 Profit Surges On One-time Gain; To Buy Back Up To S$2 Bln Of Shares

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News

Singtel reported that its net profit for the year ended on 31 March 2025 surged to S$4.017 billion from last year's S$795 million as a result of a net exceptional gain of S$1.55 billion, mainly from the partial divestment of its Comcentre headquarters, compared to a net exceptional loss a year ago.

Singtel's underlying net profit rose 9.3% to S$2.47 billion for the full year, and would have increased 11.4% in constant currency terms, driven by robust performances from Optus, NCS and regional associates Airtel and AIS.

Annual group revenue increased by 0.1% to S$14.146 billion from S$14.128 billion last year, and rose 0.8% on a constant currency basis.

Singtel's board has proposed a final one-tier tax exempt ordinary dividend of 10.0 cents per share, totalling about S$1.65 billion for the current financial year ended 31 March 2025.

The company's board has authorized a share buyback program of up to S$2 billion over the next three years until financial year 2028.

Looking ahead for fiscal year ending 31 March 2026, the company projects EBIT, excluding associates' contributions, growth rate to be in high single digits; and cost savings of approximately S$200 million in Singtel Singapore and Optus.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - April 27 – May 01, 2026

May 01, 2026 15:54 ET
Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.

RELATED NEWS
Latest Updates on COVID-19